SQ Innovation is a privately held Swiss biopharmaceutical company located in Zug, Switzerland, and Burlington, Massachusetts, United States.

Founded to develop and commercialize innovative, cost-effective therapies for subcutaneous delivery, the company aims to enable at-home treatment for conditions traditionally managed in hospitals. SQ Innovation has developed a novel drug-device combination for treating fluid overload in adult patients with chronic heart failure — a condition typically requiring intravenous administration of medications in a hospital setting. This product, Lasix® ONYU, was developed with consideration for patients, payors, healthcare providers, and environmental impact. Lasix® ONYU received Tentative Approval from the US Food and Drug Administration in October 2024.  Lasix ONYU has not been approved for sale.